MDIC is a public-private consortium - FDA, NIH, CMS, AdvaMed members, academia - that funds and coordinates regulatory science projects spanning real-world evidence, clinical trial innovation, cybersecurity, computational modeling, and case-for-quality programs. Its outputs include frameworks and tools that FDA may reference in its own guidance and review practice.

Why it matters

MDIC outputs (e.g., the Case for Quality program, CDRH's Voluntary Medical Device Manufacturing and Product Quality program) influence FDA expectations and industry practice.

Common pitfalls

•A common pitfall is misunderstanding MDIC as a regulatory body; it is a convenor and research accelerator. Another mistake is overlooking the voluntary nature of adopting MDIC outputs, which often become de-facto industry standards. Failing to engage with MDIC activities might lead to missing out on emerging regulatory science trends and pre-competitive collaborations.
•One pitfall is confusing MDIC’s recommendations with mandatory regulations, as they serve as influential guidance. Some incorrectly assume that MDIC’s focus is solely on new technologies, neglecting its efforts in improving existing regulatory processes.
•A mistake is to view MDIC as an exclusive group, rather than an inclusive consortium open to broad participation and collaboration.

Sources

MDIC · MDIC
MedTech Europe · MedTech Europe
RAPS · RAPS
Mission & Purpose · MDIC

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.